Literature DB >> 25613450

In reply.

Wilfried Tröger.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25613450      PMCID： PMC4318465          DOI： 10.3238/arztebl.2015.0011b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  13 in total

1.  Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.

Authors:  H Matthes; W E Friedel; P R Bock; K S Zänker
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

3.  Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

Authors:  Desmond Curran; Carmelo Pozzo; Jerzy Zaluski; Magdalena Dank; Carlo Barone; Vahur Valvere; Suayib Yalcin; Christian Peschel; Miklós Wenczl; Erdem Goker; Roland Bugat
Journal:  Qual Life Res       Date:  2009-07-01       Impact factor: 4.147

4.  Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.

Authors:  Wilfried Tröger; Danijel Galun; Marcus Reif; Agnes Schumann; Nikola Stanković; Miroslav Milićević
Journal:  Dtsch Arztebl Int       Date:  2014-07-21       Impact factor: 5.594

5.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2010-03-23

6.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Authors:  Sophie Gourgou-Bourgade; Caroline Bascoul-Mollevi; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Valérie Boige; Jocelyne Bérille; Thierry Conroy
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

7.  Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival.

Authors:  W Tröger; D Galun; M Reif; A Schumann; N Stanković; M Milićević
Journal:  Eur J Cancer       Date:  2013-07-24       Impact factor: 9.162

8.  Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.

Authors:  Stefan Boeck; Christiane J Bruns; Mirja Sargent; Claus Schafer; Thomas Seufferlein; Karl-Walter Jauch; Volker Heinemann
Journal:  Oncology       Date:  2009-06-25       Impact factor: 2.935

Review 9.  Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature.

Authors:  Mohamad Alshurafa; Matthias Briel; Elie A Akl; Ted Haines; Paul Moayyedi; Stephen J Gentles; Lorena Rios; Chau Tran; Neera Bhatnagar; Francois Lamontagne; Stephen D Walter; Gordon H Guyatt
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

10.  When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery.

Authors:  Horacio J Asbun; Kevin Conlon; Laureano Fernandez-Cruz; Helmut Friess; Shailesh V Shrikhande; Mustapha Adham; Claudio Bassi; Maximilian Bockhorn; Markus Büchler; Richard M Charnley; Christos Dervenis; Abe Fingerhutt; Dirk J Gouma; Werner Hartwig; Clem Imrie; Jakob R Izbicki; Keith D Lillemoe; Miroslav Milicevic; Marco Montorsi; John P Neoptolemos; Aken A Sandberg; Michael Sarr; Charles Vollmer; Charles J Yeo; L William Traverso
Journal:  Surgery       Date:  2014-01-02       Impact factor: 3.982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.